香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 內幕消息 公司擬向北京證券交易所申請A股上市 並根據特定授權發行內資股 本 公 告 乃 艾 美 疫 苗 股 份 有 限 公 司（「本公司」）按 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2)條 發 出。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，其 於2026年3月30日 已 議 決 通 過，批 准 增發內資股不超過40,000,000股（「本次發行」），不 超 過 本 次 發 行 前 本 公 司 已發行股份總數的約3.2611%，不 超 過 本 次 發 行 後 本 公 司 已 發 行 股 份 總 ...

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 1,165,673, a decrease of 9.3% compared to RMB 1,285,031 in 2024[3] - Gross profit for the same period was RMB 760,204, reflecting a decline of 20.3% from RMB 953,508 in 2024[3] - Loss attributable to equity holders of the parent company was RMB 675,460, an increase of 143.6% from RMB 277,234 in 2024[3] - The company reported a pre-tax loss of RMB 766,557, compared to RMB 290,718 in the previous year[4] - Other income and gains for the year ended December 31, 2025, totaled RMB 29,737,000, a decrease of 9.6% from RMB 32,847,000 in 2024[38] - The current income tax expense for the year ended December 31, 2025, was RMB 12,003,000, a decrease of 35.4% from RMB 18,555,000 in 2024[42] - The group did not recommend any dividend payment for the year ended December 31, 2025, consistent with 2024[45] - The company reported a net loss of RMB 743.7 million for 2025, an increase of RMB 465.3 million from a loss of RMB 278.4 million in 2024, primarily due to impairment provisions related to certain R&D projects[122] Assets and Liabilities - Total non-current assets decreased to RMB 4,501,550 from RMB 4,926,924 in 2024[7] - Current assets totaled RMB 2,042,923, down from RMB 2,387,397 in 2024[7] - Total liabilities increased slightly to RMB 3,092,944 from RMB 3,090,268 in 2024[7] - As of December 31, 2025, the net current liabilities amounted to RMB 1,050,021,000, an increase from RMB 702,871,000 in 2024[8] - Total assets minus current liabilities were recorded at RMB 3,451,529,000, down from RMB 4,224,053,000 in 2024[8] - The total non-current liabilities decreased to RMB 515,020,000 from RMB 612,945,000 in the previous year[8] - The company's equity attributable to owners of the parent was RMB 2,759,191,000, a decline from RMB 3,365,520,000 in 2024[8] Research and Development - The company incurred research and development expenses of RMB 191,275, down from RMB 363,126 in 2024[4] - The company operates five validated human vaccine technology platforms and has four wholly-owned vaccine production enterprises[54] - The company has 20 vaccine products in development across 12 disease areas, with 24 clinical approvals and 24 ongoing clinical trials, including 7 innovative vaccines in Class 1[55] - The company is actively advancing the development of its vaccine product pipeline through continuous technological innovation[75] Market and Sales - Vaccine sales accounted for RMB 1,165,662 in 2025, down from RMB 1,261,446 in 2024, representing a decline of 7.6%[35] - Revenue from mainland China was RMB 1,165,298 in 2025, compared to RMB 1,278,217 in 2024, indicating a decrease of 8.8%[32] - Revenue from other countries/regions dropped to RMB 375 in 2025 from RMB 6,814 in 2024, a decline of 94.5%[32] - The company has commercialized eight vaccine products targeting six disease areas, with recombinant hepatitis B vaccine and freeze-dried rabies vaccine being key products in the market[62] Inventory and Receivables - The company's inventory balance as of December 31, 2025, was RMB 347.4 million, a decrease of RMB 115.2 million or 24.9% from RMB 462.6 million as of December 31, 2024, primarily due to improved inventory management and provisions for near-expiry vaccines[125] - Trade receivables rose to RMB 1,241,722,000 in 2025 from RMB 1,173,906,000 in 2024, with a net trade receivable balance of RMB 1,197,595,000 after impairment[48] - The impairment loss for trade receivables decreased to RMB 44,127,000 in 2025 from RMB 51,153,000 in 2024[50] Financial Management - The company has successfully renewed bank loans amounting to RMB 134,620,000 and secured new bank loans of RMB 176,232,000 after December 31, 2025[14] - Cash and cash equivalents decreased to RMB 342,578 from RMB 494,265 in 2024[7] - The company's financing costs for 2025 were RMB 57.8 million, a decrease of RMB 3.0 million or 4.9% from RMB 60.8 million in 2024, primarily due to reduced bank loan balances and interest rates[120] Regulatory and Compliance - The group has adopted the revised International Accounting Standard No. 21 regarding the lack of exchangeability for the first time in the current financial statements[20] - The group plans to apply new and amended International Financial Reporting Standards when they become effective[21] - The company is committed to adhering to Good Manufacturing Practices (GMP) to ensure quality assurance in its production processes[152] Strategic Initiatives - The company is focused on expanding its market presence and exploring new strategies for growth[149] - The company plans to leverage its 20-year sales network and brand reputation to facilitate the market entry of new products, including the serum-free rabies vaccine[106] - The company aims to deepen cooperation with "Belt and Road" countries to address unmet medical needs globally[107] Employee and Corporate Governance - As of December 31, 2025, the company expects to have approximately 1,466 employees, increasing to about 1,535 by December 31, 2024[137] - Total employee benefit expenses, including director remuneration, are projected to be RMB 344.5 million for 2025, down from RMB 356.9 million in 2024[137] - The audit committee, consisting of three independent non-executive directors, has reviewed the financial results for the year ending December 31, 2025[143]

Core Insights - The storage industry chain is a critical pillar of the semiconductor industry, supporting various high-growth sectors such as AI servers, automotive electronics, industrial control, IoT, and cloud computing [1] - The domestic storage industry chain is experiencing a surge in orders across leading enterprises, with many companies seeing order volumes exceeding 10 billion, indicating a strong growth trajectory and a rapid pace of domestic substitution [1] Company Summaries Giantec (聚辰股份) - Founded in 2009, Giantec specializes in non-volatile storage chips and mixed-signal chips, with a global customer base [2] - Core products include DDR5 SPD chips and EEPROM chips, with a focus on high reliability for automotive and industrial applications [3] - Holds over 40% global market share in DDR5 SPD chips and ranks first in the domestic EEPROM market, benefiting from the AI server upgrade cycle with orders extending to Q1 2027 [4] Dosilicon (东芯股份) - Established in 2014, Dosilicon focuses on small to medium capacity storage chips, providing comprehensive solutions including NAND, NOR, and DRAM [5] - Main products include SLC NAND and SPI NOR Flash chips, with a complete range of automotive-grade certifications [6] - Holds over 30% market share in domestic SLC NAND, with orders extending to the end of 2026, driven by surging demand in industrial and automotive sectors [8] Ingenic (北京君正) - Founded in 2005, Ingenic is a leader in CPU and storage chips, with a strong focus on high-performance, low-power solutions for smart hardware and automotive electronics [9] - Key products include automotive-grade SRAM and DRAM chips, all meeting stringent automotive standards [10] - Holds approximately 29% global market share in automotive SRAM, with a strong order pipeline extending to the end of 2026 [11] Biwin (佰维存储) - Established in 2010, Biwin integrates R&D, packaging, testing, and sales of storage solutions, focusing on AI and embedded storage [12] - Core products include embedded storage and consumer-grade SSDs, with the ePOP module leading the global market [13] - Positioned as a leader in AI storage, with orders extending to Q1 2026, benefiting from the rapid adoption of AI devices [14] TFME (通富微电) - Founded in 1994, TFME is a leading integrated circuit packaging and testing company, providing a one-stop service from design to testing [15] - Core business includes packaging and testing for storage chips and AI accelerators, with advanced packaging technologies in mass production [17] - As a key partner for AMD, the company has a robust order pipeline extending through 2026, driven by high demand for advanced packaging [18] JCET (长电科技) - Established in 1972, JCET is a global leader in integrated circuit manufacturing and services, focusing on advanced packaging for storage chips [19] - Key products include HBM3 packaging with a high yield rate of 98.5%, serving major storage companies [20] - Orders extend to Q2 2028, benefiting from the surge in AI computing and advanced packaging demand [21] Naura (北方华创) - Founded in 2001, Naura specializes in semiconductor equipment, covering 80% of the front-end process equipment [22] - Core products include etching and deposition equipment, with significant involvement in domestic storage wafer expansion [23] - Orders extend to 2027, driven by the acceleration of domestic equipment substitution [24] Longsys (江波龙) - Established in 1999, Longsys is a leading semiconductor storage brand, focusing on enterprise, industrial, and consumer storage solutions [25] - Core products include enterprise-grade NVMe SSDs and DDR5 RDIMM modules, catering to AI server demands [26] - Orders extend to the end of 2026, supported by strong demand from domestic cloud service providers [27] Montage (澜起科技) - Montage is a leading data processing and interconnect chip design company, focusing on memory interface chips [28] - Core products include memory interface solutions from DDR2 to DDR5, with a strong market position in AI server applications [29] - Orders extend to Q1 2027, benefiting from the AI computing boom [30] GigaDevice (兆易创新) - Founded in 2005, GigaDevice is a top player in storage chip design, with a focus on NOR Flash and niche DRAM [31] - Core products include NOR Flash with approximately 19% global market share, and a strong presence in automotive and industrial storage [33] - Orders extend to the end of 2026, supported by the growing demand for AI servers and IoT devices [34]

（股 份 代 號：06660） 董事會會議通告 艾 美 疫 苗 股 份 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2026年3月30日（星 期 一）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及其附屬公司截至2025年12月31日 止 年 度 的 年 度 業 績 及 其 發 佈，並 考 慮 建 議 派 發 末 期 股 息（如 有），以 及 處 理 其 他 事 項。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 董事會主席兼CEO 周延先生 香 港，2026年3月18日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 事 周 延 先 生、周 欣 先 生、 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 艾美疫苗股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 2 ...

Company Progress - The company has made significant progress in its research pipeline, with its first global serum-free rabies vaccine successfully passing the National Medical Products Administration's registration site inspection on February 5, 2026, bringing the product closer to market launch [2] - Several key products, including the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), are in the final stages before market launch [2] Stock Performance - Despite the advancements, the stock price of the company (06660.HK) has recently experienced a decline, closing at HKD 3.03 on February 12, 2026, down 5.90% for the day and a cumulative drop of 18.98% over the past 20 trading days [3] - The stock price fluctuations may be influenced by several factors, including the overall market environment, with the Hong Kong stock market showing volatility and the Hang Seng Index declining during the same period [3] - Short-term performance pressures are evident, with the company's revenue for the first half of 2025 at RMB 515 million, a slight decrease of 4.2% year-on-year, primarily due to a decline in revenue from its core rabies vaccine [3] - Although losses have narrowed year-on-year, short-term performance volatility may affect market sentiment, and the company continues to require ongoing investment in R&D before significant revenue contributions from new products can be realized [3]

Core Viewpoint - The demand for safer and more effective rabies vaccines is increasing due to a rise in rabies cases and deaths, highlighting the urgency for innovative solutions in the market [1][2]. Group 1: Product Development - Aimee Vaccine's serum-free iterative rabies vaccine has successfully passed clinical trial inspections by the National Medical Products Administration, indicating it is closer to market launch [1]. - The Phase III clinical trial results show that the serum-free iterative rabies vaccine has good safety, immunogenicity, and durability, meeting all preset evaluation standards [1]. - Unlike traditional rabies vaccines, Aimee's serum-free vaccine does not contain animal serum, significantly improving safety and reducing adverse reactions [1]. Group 2: Market Context - Rabies remains a severe public health challenge globally, with approximately 40 million people exposed to rabies in China each year, and the vaccination rate for exposed individuals is only about 35% [2]. - After four consecutive years of decline, rabies cases and deaths in China are projected to rise again starting in 2024, with 244 reported cases and 233 deaths in 2025, marking the highest figures since 2020 [2]. - The increase in rabies cases indicates a persistent and urgent need for upgraded rabies vaccines in the market [2]. Group 3: Market Position and Strategy - Aimee Vaccine is the second-largest rabies vaccine producer globally, with a comprehensive product matrix covering various technologies, including serum-free and mRNA vaccines, positioning the company as a dominant player in the domestic market [2]. - The company has established a sales network covering all 31 provinces in China, facilitating rapid market penetration for new products [3]. - Aimee Vaccine is also expanding into international markets, exporting rabies vaccines to emerging markets such as Pakistan, Egypt, Tajikistan, and Côte d'Ivoire, which may provide new growth opportunities [3]. Group 4: Financial Outlook - Aimee Vaccine is entering a critical phase with the upcoming launch of innovative products, supported by its strong R&D, production, and commercialization capabilities [4]. - Analysts predict the company's net profit could reach 883 million yuan and 1.52 billion yuan by 2027, indicating potential for significant growth as multiple innovative vaccines enter the market [4]. - The company is expected to play an increasingly important role in both the domestic and global high-end vaccine markets as it achieves substantial performance growth [4].

Core Insights - The demand for safer and more effective rabies vaccines is increasing due to a rise in rabies cases and deaths in recent years [1][2] Group 1: Product Development - Aimee Vaccine's serum-free iterative rabies vaccine has successfully passed clinical trial inspections by the National Medical Products Administration, indicating it is closer to market launch [1] - The Phase III clinical trial results show that the serum-free iterative rabies vaccine has good safety, immunogenicity, and durability, meeting all preset evaluation standards [1] - Unlike traditional rabies vaccines, the serum-free version does not contain animal serum, significantly improving safety and reducing adverse reactions [1] Group 2: Market Context - Rabies remains a severe public health challenge globally, with approximately 40 million people exposed to rabies in China each year, and only about 35% of exposed individuals receiving vaccination [2] - After four consecutive years of decline, rabies cases and deaths in China are projected to rise again starting in 2024, with 244 reported cases and 233 deaths in 2025, the highest since 2020 [2] - This trend indicates a persistent and urgent need for upgrades in the rabies vaccine market [2] Group 3: Competitive Position - Aimee Vaccine is the second-largest rabies vaccine producer globally, with a comprehensive product matrix covering various technologies, including serum-free and mRNA vaccines [2] - The company has established a nationwide sales network across 31 provinces in China, facilitating rapid market penetration for new products [3] - Aimee Vaccine is also expanding into international markets, exporting rabies vaccines to emerging markets such as Pakistan, Egypt, Tajikistan, and Côte d'Ivoire, which may provide new growth opportunities [3] Group 4: Financial Outlook - Aimee Vaccine is entering a critical phase with the upcoming launch of innovative products, supported by its strong R&D, production, and commercialization capabilities [4] - Analysts predict the company's net profit could reach 883 million RMB and 1.52 billion RMB by 2027, indicating potential for significant growth [4] - The introduction of multiple innovative vaccines is expected to lead to a substantial increase in performance, positioning Aimee Vaccine as a key player in both domestic and global high-end vaccine markets [4]

Major Events - Genting New Year (01952) subsidiary signed an agreement with Macao to commercialize MT1013 in Greater China and other Asian markets [1] - Junshi Biosciences (02696) entered into a licensing agreement with Eisai for Hansizhuang® to treat tumor indications [1] - Meituan-W (03690) plans to acquire all issued shares of Dingdong Fresh Holding Limited [1] - China Power (02380) subsidiary Xinyuan Zhichu signed a procurement contract for BESS with Tori [1] - Aimee Vaccine (06660) successfully passed the registration site inspection for its globally self-researched serum-free rabies vaccine [1] Operating Performance - NIO-SW (09866) issued a profit warning, expecting adjusted operating profit of 700 million to 1.2 billion yuan in Q4 2025, turning from loss to profit year-on-year [1] - Saint Bella (02508) issued a profit warning, expecting adjusted net profit of no less than 120 million yuan for 2025, a year-on-year increase of no less than 183% [1] - Geek+ (02590) achieved orders of 4.137 billion yuan in 2025, a year-on-year growth of approximately 31.7% [1] - China Overseas Development (00688) achieved contract property sales of approximately 14.478 billion yuan in January, a year-on-year increase of 20.4% [1] - Swire Properties (01972) reported a rental rate of 96% for Swire Plaza in Q4, with rents down by 13% [1] - Greentown China (03900) reported total contract sales of approximately 9.7 billion yuan in January, a year-on-year decrease of 14.16% [1]

Core Viewpoint - The company has achieved a significant technological breakthrough with its serum-free iterative rabies vaccine, which is expected to fill a market gap as it is the first of its kind to be approved for sale globally [1][2] Group 1: Product Development and Approval - The company's subsidiary, Aimeirongyu (Ningbo) Biopharmaceutical Co., Ltd., has successfully passed the clinical trial site inspection and drug registration production site inspection for its serum-free iterative rabies vaccine [1] - The Phase III clinical study results indicate that the vaccine demonstrates good safety, immunogenicity, and durability, meeting all preset evaluation standards [1] - The company has obtained the necessary production license for the serum-free iterative rabies vaccine, positioning itself for a market launch [1] Group 2: Market Potential and Competitive Advantage - China is the largest rabies vaccine market globally, projected to reach 14.8 billion yuan by 2030, driven by product updates and increased vaccine adoption [2] - The new vaccine's lack of animal serum significantly enhances safety and reduces the likelihood of adverse reactions, making it a preferred choice for vaccination institutions [2] - As the second-largest supplier of rabies vaccines globally, the company aims to lead in the deep technological iteration and upgrade of rabies vaccines, with the capability for large-scale production once the product is approved [2]